The FDA told GlaxoSmithKline on July 20 to stop enrolling new patients in a trial of the diabetes drug Avandia, while letting the study continue. Public Citizen's Sidney Wolfe called that going only halfway; an FDA advisory panel had voted 20 to 12 to keep the drug on the market.
Section archive
Glaxo
- All desks
- Abortion
- Accutane
- Acetaminophen
- Acid Reflux
- Acidic Foods
- Acne
- Acrylamide
- Acupuncture
- Additives
- ADHD
- Adiposity
- Advisories
- Aerobic Exercise
- Aflatoxin
- Agave
- Agent Orange
- Aging
- Agriculture
- AIDS
- Air Pollution
- Airline Passengers
- Airport
- ALA
- Alcohol
- Alcoholic Beverage
- Alerts
- Allergy
- Alli
- Aloe Vera
- ALS
- Alternative Medicine
- Aluminum
- Alzheimer's
- Amalgam
- AMD
- Ampyra
- Amygdala
- Anal Cancer
- And
- Anemia
- Angiogenesis
- Animal Protein
- Animals
- Anorexia
- Anthocyanins
- Anthrax
- Anti-Angiogenesis
- Anti-Obesity
- Antibacterial
- Antibiotic
1 story